Inventor · disambiguated record
Mariola Fotin-Mleczek
Also filed as: FOTIN-MLECZEK MARIOLA
26 granted patents·55 pending applications·690 citations·filing 2006–2025
97Inventor score
Top patents by PatentIndex Score
81 records- 0199US11078247B2RNA encoding a therapeutic proteinCUREVAC AG·Filed 2017·Granted Aug 3, 2021·57 cites·18 claims
- 0299US10434158B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Oct 8, 2019·31 cites·21 claims
- 0399US10117920B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2018·Granted Nov 6, 2018·32 cites·12 claims
- 0498US11458195B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2019·Granted Oct 4, 2022·12 cites·25 claims
- 0598US10293058B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2016·Granted May 21, 2019·50 cites·16 claims
- 0697US11110157B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2019·Granted Sep 7, 2021·28 cites·13 claims
- 0797US11110166B2Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvantCUREVAC AG·Filed 2019·Granted Sep 7, 2021·32 cites·20 claims
- 0897US10918740B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2018·Granted Feb 16, 2021·38 cites·19 claims
- 0997US10568958B2Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugatesCUREVAC AG·Filed 2016·Granted Feb 25, 2020·30 cites·12 claims
- 1097US10307472B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2014·Granted Jun 4, 2019·31 cites·13 claims
- 1197US10111967B2Complexes of RNA and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2013·Granted Oct 30, 2018·30 cites·25 claims
- 1297US9974845B2Combination of vaccination and inhibition of the PD-1 pathwayCUREVAC AG·Filed 2014·Granted May 22, 2018·32 cites·10 claims
- 1396US10869935B2RNA containing composition for treatment of tumor diseasesCUREVAC AG·Filed 2019·Granted Dec 22, 2020·29 cites·23 claims
- 1496US10369216B2Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvantCUREVAC AG·Filed 2015·Granted Aug 6, 2019·29 cites·17 claims
- 1595US11596699B2RNA encoding an antibodyCureVac SE·Filed 2017·Granted Mar 7, 2023·11 cites·19 claims
- 1695US11559570B2Prime-boost regimens involving administration of at least one mRNA constructCureVac SE·Filed 2016·Granted Jan 24, 2023·8 cites·22 claims
- 1794US10988754B2Nucleic acid moleculesCUREVAC AG·Filed 2018·Granted Apr 27, 2021·51 cites·21 claims
- 1894US9572874B2Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereofFOTIN-MLECZEK MARIOLA·Filed 2009·Granted Feb 21, 2017·76 cites·22 claims
- 1994US9421255B2Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugatesBAUMHOF PATRICK·Filed 2012·Granted Aug 23, 2016·34 cites·19 claims
- 2093US11690910B2Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigenCureVac SE·Filed 2019·Granted Jul 4, 2023·6 cites·20 claims
- 2193US11458193B2Combination of vaccination and inhibition of MHC class I restricted antigen presentationCUREVAC AG·Filed 2017·Granted Oct 4, 2022·11 cites·10 claims
- 2289US9737595B2Combination of vaccination and inhibition of MHC class I restricted antigen presentationLORENZ CHRISTINA·Filed 2011·Granted Aug 22, 2017·29 cites·16 claims
- 2386US2025302932A1Combination of vaccination and ox40 agonistsCureVac SE·Filed 2024·Application pending·0 cites
- 2484US12447209B2Combination of vaccination and inhibition of the PD-1 pathwayCureVac SE·Filed 2022·Granted Oct 21, 2025·0 cites·35 claims
- 2583US2025084141A1Rna encoding a therapeutic proteinCureVac SE·Filed 2024·Application pending·0 cites
- 2681US2025213724A1Rna containing composition for treatment of tumor diseasesCureVac SE·Filed 2025·Application pending·0 cites
- 2781US2023338579A1Rna containing composition for treatment of tumor diseasesCureVac SE·Filed 2022·Application pending·0 cites
- 2878US2024101608A1Optimized nucleic acid moleculesCureVac SE·Filed 2023·Application pending·0 cites
- 2978US2021060175A1Methods of immunostimulation with complexes of rna and cationic carriersCUREVAC AG·Filed 2020·Application pending·0 cites
- 3077US2025288522A1LIPID NANOPARTICLE mRNA VACCINESCureVac SE·Filed 2025·Application pending·0 cites
- 3176US12178863B2Combination of vaccination and OX40 agonistsCUREVAC AG·Filed 2021·Granted Dec 31, 2024·0 cites·14 claims
- 3275US2019175756A1METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA)CUREVAC AG·Filed 2019·Application pending·0 cites
- 3375US2019175758A1METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS)CUREVAC AG·Filed 2019·Application pending·0 cites
- 3475US2019175757A1METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXINCUREVAC AG·Filed 2019·Application pending·0 cites
- 3575US2019175759A1METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB)CUREVAC AG·Filed 2019·Application pending·0 cites
- 3675US2019175760A1METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC)CUREVAC AG·Filed 2019·Application pending·0 cites
- 3775US2019167808A1Methods of treating phenylketonuria with mrna encoding phenylalanine hydroxylase (pah)CUREVAC AG·Filed 2019·Application pending·0 cites
- 3875US2019167809A1METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8)CUREVAC AG·Filed 2019·Application pending·0 cites
- 3974US12227549B2RNA encoding a therapeutic proteinCureVac SE·Filed 2021·Granted Feb 18, 2025·0 cites·21 claims
- 4073US2018311379A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4173US2024075116A1Rna encoding a tumor antigenCureVac SE·Filed 2023·Application pending·0 cites
- 4272US2018169267A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4372US2018169266A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4472US2018161454A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4572US2018236102A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4672US2018161452A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4772US2023210965A1PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCTCureVac SE·Filed 2022·Application pending·0 cites
- 4872US2018161451A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
- 4972US2023293731A1Rna encoding an antibodyCureVac SE·Filed 2022·Application pending·0 cites
- 5072US2018161453A1Complexes of rna and cationic peptides for transfection and for immunostimulationCUREVAC AG·Filed 2018·Application pending·0 cites
Showing the top 50 of 81 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mariola Fotin-Mleczek files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →